Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 2,707 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the transaction, the director now directly owns 517,030 shares in the company, valued at approximately $79,064,227.60. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kevin Charles Gorman also recently made the following trade(s):

• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded up $2.32 during trading hours on Tuesday, hitting $152.42. 814,308 shares of the company were exchanged, compared to its average volume of 950,096. The company has a 50 day simple moving average of $137.92 and a two-hundred day simple moving average of $131.51. The firm has a market cap of $15.43 billion, a P/E ratio of 40.86 and a beta of 0.33. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cetera Investment Advisers increased its position in Neurocrine Biosciences by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock valued at $979,000 after buying an additional 519 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $510,000. Handelsbanken Fonder AB raised its position in shares of Neurocrine Biosciences by 20.7% during the third quarter. Handelsbanken Fonder AB now owns 26,867 shares of the company’s stock worth $3,096,000 after purchasing an additional 4,600 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Neurocrine Biosciences by 11.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after purchasing an additional 185 shares in the last quarter. Finally, CWM LLC increased its stake in Neurocrine Biosciences by 15.1% during the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after purchasing an additional 1,035 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NBIX. BMO Capital Markets dropped their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. UBS Group raised their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. Barclays upped their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Morgan Stanley increased their price target on Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.85.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.